Advertisement
Imaging
Subscribe to Imaging
View Sample

FREE Email Newsletter

HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council

October 4, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

BRANFORD, Conn., Oct. 4 /- HistoRx was recognized as a 2010 Company to Watch by the Connecticut Technology Council at the Innovation Pipeline Awards ceremony last week in New Haven, Connecticut.  HistoRx was recognized for significant milestones achieved in 2010: launching its...

PolyTouch Medical to Attend the American College of Surgeons 96th Annual Clinical Congress, Washington DC. (Booth #549)

October 4, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

PolyTouch Medical to Attend the American College of Surgeons 96th Annual Clinical... -- MISGAV, Israel, October 4, 2010 /-

Cable Technology Meets Requirements for High Data-Rate Applications

October 4, 2010 5:31 am | W.L. Gore & Associates | Product Releases | Comments

This technology consists of a new differential cable design with lower SCD21 (differential-to-common-mode conversion) and a very high level of signal fidelity.

Advertisement

Ziehm Imaging Provides Germany's Federal Armed Forces (Bundeswehr) With Mobile X-Ray Systems

October 4, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

Ziehm Imaging Provides Germany's Federal Armed Forces (Bundeswehr) With Mobile X-Ray Systems -- NUREMBERG, Germany, October 4, 2010 /-

Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash

October 4, 2010 1:33 am | by Bio-Medicine.Org | News | Comments

PARIS, Oct. 4 /- Sanofi-aventis [(EURONEXT: SAN) and (NYSE: SNY)] announced today it has commenced a tender offer for all outstanding shares of common stock of Genzyme Corporation (Nasdaq: GENZ ) for $69 per share, net to the seller in cash, without interest and less any required...

Peptimmune Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone

October 4, 2010 1:33 am | by Bio-Medicine.Org | News | Comments

SOMERVILLE, Mass., Oct. 4 /- Peptimmune, Inc. announced today that it has filed a technically focused Citizen Petition requesting that the FDA not approve any application for a generic version of Copaxone® [glatiramer acetate injection] (Teva Pharmaceuticals). "We feel that it is...

New American Therapeutics Acquires Antiviral Drug Denavir®

October 3, 2010 11:33 pm | by Bio-Medicine.Org | News | Comments

CRANFORD, N.J., Oct. 4 /- New American Therapeutics, Inc., announced today that it acquired all U.S. rights to manufacture, market and sell the antiviral topical drug Denavir® owned by Novartis.  Denavir (1% penciclovir cream) is a highly selective and potent topical antiviral...

Disparities 2010: Interview with Charles M. Perou, Ph.D.

October 1, 2010 12:32 pm | by AACR | News | Comments

Disparities 2010: Interview with Charles M. Perou, Ph.D., professor of genetics, pathology and laboratory medicine, University of North Carolina, Chapel Hill

Advertisement

Disparities 2010: Interview with William G. Nelson, M.D., Ph.D.

October 1, 2010 12:31 pm | by AACR | News | Comments

Dr. Nelson discusses the most common cancer disparity among men, his activity on AACR’s new survivorship research task force, and his experience reviewing the exciting research proposals for Stand Up To Cancer in this wide-ranging interview.

NCPA: Walmart Medicare Drug Plan a Prescription for Poor Pharmacy Care

October 1, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

ALEXANDRIA, Va., Oct. 1 /PRNewswire-USNewswire/ -- Wal-Mart Stores, Inc., the world's largest corporation, today announced a Medicare prescription drug plan that imposes higher co-payments on seniors who choose to continue using their trusted local, community pharmacy. (Logo:...

Best Practices, LLC Research Highlights Evolving Role of Market Research in Organizational Success

October 1, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

CHAPEL HILL, N.C., Oct. 1 /- The pharmaceutical and biotechnology sectors have long turned to the market research function to help organizations navigate the competitive landscape. As the marketplace has evolved, leading organizations have learned that the market research function needs...

New National Program to Study and Establish Pediatric Dosing

October 1, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

KANSAS CITY, Mo., Oct. 1 /- A new national initiative, the Pediatric Trials Network (PTN), was created this week with a $95 million grant supported by the National Institutes of Health (NIH).  The PTN will be led through collaboration between the Eunice Kennedy Shriver National...

New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease

October 1, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

FORT LEE, N.J., Oct. 1 /- Neurologix, Inc. (OTC Bulletin Board: NRGX ), today announced that new details of the company's landmark, randomized, double-blind Phase 2 clinical trial of NLX-P101, its investigational gene therapy for advanced Parkinson's disease (PD), were presented during a...

Advertisement

CVS Caremark Recognizes Its 26,000 Pharmacists During October's American Pharmacists Month

October 1, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

WOONSOCKET, R.I., Oct. 1 /- October is American Pharmacists Month and CVS Caremark is recognizing its 26,000 pharmacists who provide outstanding care to their patients every day in its retail pharmacies, mail service pharmacies and specialty pharmacies across the country. (Logo:...

DMC Sinai-Grace Selects Loopback Communications' Readmission Reduction™ Services

October 1, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

DALLAS, Oct. 1 /- DMC Sinai-Grace Hospital has selected Dallas-based Loopback Communications' technology-leading Readmission Reduction™ solution to support its efforts to reduce readmissions of discharged patients. "DMC Sinai-Grace is committed to continuous quality improvement and...

Disparities 2010: Interview with Howard K. Koh, M.D., M.P.H

October 1, 2010 9:32 am | by AACR | News | Comments

Disparities 2010: Interview with Howard K. Koh, M.D., M.P.H., assistant secretary for health, U.S. Department of Health and Human Services

Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet

October 1, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

BRIDGEWATER, N.J., Oct. 1 /- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published in the...

VirtualScopics Revenues Hit Another Quarterly Record

October 1, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

ROCHESTER, N.Y., Oct. 1 /- VirtualScopics, Inc. (Nasdaq: VSCP ), a provider of quantitative imaging for clinical trials, today announced revenues for the third quarter ended September 30, 2010 exceeded $3.5 million, representing a greater than 25% increase over the comparable period in...

Elekta Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer

October 1, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Oct. 1 /- Elekta recently launched ABAS ( Atlas-based Autosegmentation ) 2.0 software, which includes the Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm to increase contouring accuracy. ABAS—considered the industry gold standard for autosegmentation...

Cancer Health Disparities: Challenges and Opportunities

October 1, 2010 7:34 am | by AACR | News | Comments

Disparities 2010: “Cancer Health Disparities: Challenges and Opportunities” includes perspectives from numerous Congressional officials, Federal agency leaders and a clinician on possible policy prescriptions that are necessary to help reduce cancer health disparities.

Mylan Launches Generic Version of Wellbutrin XL® Tablets

October 1, 2010 3:32 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Oct. 1 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL...

Disparities 2010: Interview with Eddie Reed, M.D.

September 30, 2010 3:34 pm | by AACR | News | Comments

Disparities 2010: Eddie Reed, M.D., clinical director, University of South Alabama Mitchell Cancer Institute Dr. Reed talks about the challenges of health disparities he experiences in his work, the recruitment and retention of members of minority populations in cancer clinical trials and...

FDA Orders Halt to Marketing of Unapproved Single-Ingredient Oral Colchicine

September 30, 2010 1:33 pm | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., Sept. 30 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat...

HHS Awards $473 Million in Patient-Centered Outcomes Research Funding

September 30, 2010 1:33 pm | by Bio-Medicine.Org | News | Comments

ROCKVILLE, Md., Sept. 30 /PRNewswire-USNewswire/ -- HHS' Agency for Healthcare Research and Quality today announced the award of $473 million in grants and contracts to support projects that will help people make health care decisions based on the best evidence of effectiveness. The...

New Multi-Center Study Finds Clinical Practice Change with Masimo SET Pulse Oximetry Reduces Severe Eye Damage More Than 50% in Premature Newborns

September 30, 2010 1:33 pm | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., Sept. 30 /- Masimo (Nasdaq: MASI ) announced today that a new multi-center study published in the International Peer-Reviewed Academic Journal, Acta Paediatrica, shows that a change in clinical practice with the use of Masimo SET pulse oximetry technology led to a...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading